1[1]Libermore DM. Determinants of the activity of β-lactamase inhibitor combinations. J Antimicrob Chemother, 1993, 31 (Suppl A):9
2[2]Jones RN, Pfaller MA,Doern GV, et al. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs:a 1997 surveillance trial in 102 medical centers in the United States. Diagn Microbiol Inect Dis,1998,30:215
3[3]Pfaller MA,Jones RN,Doern GV,et al. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Veneauela using the E test method. Diagn Microbiol Infect Dis,1998,30:45
4[4]Marshall SA,Aldridge KE, Allen SD, et al. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis, 1995,21:153
5[5]Klepser ME,Marangos MN ,Zhuz, et al. Comparation of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Antimicrob Agents Chemother, 1997,41:435
6[6]Shales DM, Norden C. Piperacillin-tazobactam compared to ticarcillin-clavulanate in community-acquired bacterial lower respiratory tract infection. 33rd ICAAC,New orleans, Louisianna, USA1993,Abstract 646
7[7]Tan JS,Wishnow RM,Talan DA, et al. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind ,randomized ,multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicro Agent Chemothe, 1993,37:1580
8[8]Comerra A, Zinner S, Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother, 1995,39:445
5Gin A, Dilay L, Karlowsky J A, et al. Piperacillin-tazobam : a beta-lactam/beta-lactamase inhibitor combinatrion [ J ]. Exp Rew Anti Infect Ther ,2007 ,5 ( 3 ) :365-383.
6Sudo F, Ishiwada N, Hoshino T, et al. Clinical effects of piperacillin and tazobactam/piperacillin on Haemophilus influenzae lower respiratory tract infection in pediatric patients [ J ]. Kansenshogaku Zasshi,2005 ,79( 9 ) :637-643.
7Platsouka E,Zissis N P, Portolos J, et al. Bacterial susceptilities to pipemcllin/tazobactam in a tertiary care hospital: 5-year review [J]. Chemother,2003,15( 1 ) :27-30.
8Pfaller M A, Jones R N, Doem G V, et al. Multicener evaluation of the antimicrobial activity for six broad-spectrum betalactams in Veneauela using the E test method [ J ]. Diagn Microbiol Infect Dis, 1998,30:45 - 46.
9Pereira F A, Mudgil A V, Rosmarin D M. Toxic epidermal necrol- ysis[J].Journal of the American Academy of Dermatology, 2007,56 (2):181-195.
10Roujeau J C, Kelly J P, NaldiL,et al. Medication use and the risk of steven-johnson syndrome or toxic epidermal necrolysis[J].The New England Journal of Medicine, 1995,333(24): 1600-1607.
